CompanyOCULNasdaqBedford, MA

Ocular Therapeutix, Inc.

Ocular Therapeutix develops therapies using its ELUTYX bioresorbable hydrogel platform.

SEC EDGAR ClinicalTrials.gov ocutx.com

10-QAug 13Latest SEC filing, period to Jun 30

Aug 3Latest story

August 2026

Ocular Therapeutix targets Q4 2026 AXPAXLI NDA filing for wet AMD after FDA meeting

Aug 3Quarterly updateOcular Therapeutix, Inc.